AbbVie to expand RNA capabilities with $2.1bn acquisition of Capstan Therapeutics
As part of the deal, AbbVie will acquire Capstan's candidate CPTX2309, in Phase 1 trials, and its tLNP platform for targeted RNA delivery.
Sobi secures FDA approval for Gamifant to treat MAS in Still’s disease
XtalPi, Pfizer expand collaboration to advance AI-driven drug discovery
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection
Hikma Pharmaceuticals to invest $1bn to boost US medicine production
KalVista and Pendopharm to collaborate on HAE candidate sebetralstat in Canada
Analysis
View MoreThe ultimate hub for fine and speciality chemicals
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery